675149-01-6

Basic information

• Product Name: 4-Piperidinecarboxylic acid, 1-(aminothioxomethyl)-, ethyl ester
• Synonyms: 4-Piperidinecarboxylic acid, 1-(aminothioxomethyl)-, ethyl ester;ethyl 1-carbamothioylpiperidine-4-carboxylate
• CAS NO: 675149-01-6
• Molecular Formula: C₉H₁₆N₂O₂S
• Molecular Weight: 216.3
• Mol File: 675149-01-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Piperidinecarboxylic acid, 1-(aminothioxomethyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinecarboxylic acid, 1-(aminothioxomethyl)-, ethyl ester(675149-01-6)
• EPA Substance Registry System: 4-Piperidinecarboxylic acid, 1-(aminothioxomethyl)-, ethyl ester(675149-01-6)

Safety Data

• Hazardous Substances Data: 675149-01-6(Hazardous Substances Data)

Upstream product

• 1126-09-6 4-carbethoxypiperidine 
• 2290-65-5 trimethylsilyl isothiocyanate 
• 199915-38-3 9-fluorenylmethoxycarbonyl isothiocyanate 

Downstream Products

• 847406-64-8 1-[4-(2,3-dichloro-phenyl)-thiazol-2-yl]-piperidine-4-carboxylic acid ethyl ester 
• 1207618-58-3 ethyl 1-[4-(5-fluoro-2-hydroxyphenyl)-1,3-thiazol-2-yl]-4-piperidinecarboxylate 
• 1207618-04-9 ethyl 1-[4-(2-hydroxy-5-methylphenyl)-1,3-thiazol-2-yl]-4-piperidinecarboxylate 
• 1207618-06-1 ethyl 1-{4-[2-hydroxy-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}-4-piperidinecarboxylate 
• 1207618-05-0 ethyl 1-[4-(5-ethyl-2-hydroxyphenyl)-1,3-thiazol-2-yl]-4-piperidinecarboxylate 
• 1207618-23-2 ethyl 1-[4-(2-hydroxyphenyl)-5-methyl-1,3-thiazol-2-yl]-4-piperidinecarboxylate 
• 1312573-00-4 ethyl 1-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]piperidine-4-carboxylate 
• 1312572-64-7 1-[4-(3-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]piperidine-4-carboxamide 
• 1312572-63-6 1-[4-(3-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]piperidine-4-carboxylic acid 
• 1312573-02-6 ethyl 1-[4-(3-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]piperidine-4-carboxylate 
• 1312573-01-5 ethyl 1-[4-(3-aminophenyl)-1,3-thiazol-2-yl]piperidine-4-carboxylate 

Relevant articles and documents

AMINOPYRIMIDINES AS SYK INHIBITORS

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, CF3 and OCF3; -Y- represents formula (IA) R3 represents hydrogen, fluoro, chloro or C1-4alkyl; R4a and R4b each independently represent hydrogen, C1-4alkyl, C1-4alkoxy, CF3 or halo; and R5 represents a group Z-X; wherein Z is absent or represents (CH2)2 or O; and X represents formula (IB) wherein: J and L both represent CH, or one of J and L represents CH and the other represents N; when both J and L represent CH, R6 represents hydrogen, halo, CF3, C1-4alkyl or C1-4alkoxy in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, OCF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; or when one of J or L represents N, R6 represents hydrogen or halo in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; and R8 and R9 are independently selected from hydrogen and C1-4alkyl; or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in medicine, and processes for their preparation.

Novel aminopyridine compounds having Syk inhibitory activity

The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X1, X2, Xsup

ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF

Compounds that are VLA-1 integrin antagonists are disclosed. Also disclosed are compositions containing such compounds and methods of using such compounds in treating diseases mediated, at least in part, by the VLA-1 integrin.